drugset / Trial / NCT00862992
Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be administered to patients starting at an initial dose, followed by up-titration to a fixed dose (low, medium or high) for 14 days.
Timeline
- Start
- 2008-04
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cariprazine | Small molecule | 3 mg | Oral |
| Subject | Cariprazine | Small molecule | 6 mg | Oral |
| Subject | Cariprazine | Small molecule | 12.5 mg | Oral |